Similar articles

• Medical utilization associated with palivizumab compliance in a commercial and managed medicaid health plan.

  Diehl JL, Daw JR, Coley KC, Rayburg R. Diehl JL, et al. J Manag Care Pharm. 2010 Jan-Feb;16(1):23-31. doi: 10.18553/jmcp.2010.16.1.23. J Manag Care Pharm. 2010. PMID: 20044844 Free PMC article.
• Description of the outcomes of prior authorization of palivizumab for prevention of respiratory syncytial virus infection in a managed care organization.

  Buckley BC, Roylance D, Mitchell MP, Patel SM, Cannon HE, Dunn JD. Buckley BC, et al. J Manag Care Pharm. 2010 Jan-Feb;16(1):15-22. doi: 10.18553/jmcp.2010.16.1.15. J Manag Care Pharm. 2010. PMID: 20044843 Free PMC article.
• Direct cost analyses of palivizumab treatment in a cohort of at-risk children: evidence from the North Carolina Medicaid Program.

  Wegner S, Vann JJ, Liu G, Byrns P, Cypra C, Campbell W, Stiles A. Wegner S, et al. Pediatrics. 2004 Dec;114(6):1612-9. doi: 10.1542/peds.2004-0959. Pediatrics. 2004. PMID: 15574623
• Palivizumab prophylaxis of respiratory syncytial virus infection in high-risk infants.

  Vogel AM, Lennon DR, Broadbent R, Byrnes CA, Grimwood K, Mildenhall L, Richardson V, Rowley S. Vogel AM, et al. J Paediatr Child Health. 2002 Dec;38(6):550-4. doi: 10.1046/j.1440-1754.2002.00057.x. J Paediatr Child Health. 2002. PMID: 12410864 Review.
• Prevention of respiratory syncytial virus infection with palivizumab.

  Thomas M, Bedford-Russell A, Sharland M. Thomas M, et al. Monaldi Arch Chest Dis. 2000 Aug;55(4):333-8. Monaldi Arch Chest Dis. 2000. PMID: 11057088 Review.